HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 6, June 2016 – Medical Devices & Healthcare Technology       » Seizing Opportunity in Asia-Pacific's Complex and Rapidly Changing Medical Device Market       » IoT in Healthcare       » High Performance Computing Cluster (HPC), Pearcey, a Result of CSIRO-Dell Partnership       » SONY Expanding Footprint in Medical Field       » Biosensors Announces Strategic Agreement with Cardinal Health       » Gene Decides How Young We Look      
EYE ON CHINA
SIMM explores a novel cationic core-shell lipo-nanoparticles for ocular gene drug delivery
Ocular diseases are usually treated with a topical application of drug solutions (i.e. eye drops). These traditional dosage forms account for nearly 90% of currently available marketed formulations. However, ocular physiological barriers and the poor water solubility of drug candidates present a number of problems for the development of ocular drug delivery systems.

Recently, various ophthalmic drug delivery strategies aim at improving the bioavailability of poor soluble ocular drugs have emerged. Among them, lipid-based nanocarriers exhibit a variety of potential advantages as delivery systems for ocular administration. New technological advances and unmet clinical needs provide a key driving force for the research and development of lipid-based nanocarriers for ocular drug delivery.

A novel ocular gene drug delivery system by utilizing cationic core-shell liponanoparticles (DLCS-NP) has been published on Biomaterials. Researchers led by Dr. Gan Yong from the Shanghai Institute of Materia Medica designed the DLCS-NP by hydration of thin lipid film with chitosan nanoparticle (CS-NP) suspension, followed by post-insertion of the cationic phospholipid DOTAP (1,2-dioleoyl-3- trimethylammonium-propane). This specific delivery strategy has multiple functions, including better DNA protecting effect, good cellular uptake efficiency, utilization of multiple endocytic pathways, and endolysosome escaping ability.

The study was supported by the Natural Sciences Foundation of Shanghai China and the National Natural Sciences Foundation of China, and partially supported by National Science & Technology's Major Project — “Key New Drug Creation and Manufacturing Program”, and the National Basic Research Program of China.

Click here for the complete issue.

NEWS CRUNCH  
news Gather China & World Pharmaceutical Entrepreneurs, Create a New Chapter of Chinese Pharma Industry
news Mundipharma's New Betadine® Facility to Meet Regional Healthcare Challenges
news STRATASYS launches World's First Full-ColoUr Multi-material 3D PRINTER - THE J750 - In Singapore
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Healthcare Technology Outlook 2020 - Technology uptake
COLUMNS  
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices & Healthcare Technology
July:
Water Technology and Management
August:
Novel Technologies for Antibody Drug Discovery in Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Biomedical Imaging Technology
December:
Food Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com or Mr Edward
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy